<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02104908</url>
  </required_header>
  <id_info>
    <org_study_id>PARA-2014</org_study_id>
    <nct_id>NCT02104908</nct_id>
  </id_info>
  <brief_title>Study of Nerve Block Anesthesia for Surgery of Hip Fracture in the Elderly</brief_title>
  <official_title>Target-controlled Propofol Infusion as a Technique of Anesthesia for Surgery of Hip Fracture Under Ultrasound Guidance Lumbar and Sacral Plexus Block or Lumbar, Sacral and Paravertebral Nerve Block in the Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University Affiliated Sixth People’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University Affiliated Sixth People’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to examine target-controlled propofol infusion as a technique of
      anesthesia for surgery of hip fracture under ultrasound guidance lumbar and sacral plexus
      block or lumbar, sacral and paravertebral nerve block in the elderly; and to evaluate which
      regional anesthesia was more sufficient for the old.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eighty patients with American Society of Anesthesiologists（ASA） Ⅰ-Ⅲ older than 80 years are
      randomly assigned to 2 groups: a lumbar and sacral plexus block(LS) group with 20ml 0.5%
      ropivacaine at lumbar plexus(level L3-4) and 10ml 0.5%ropivacaine at sacral plexus; a lumbar,
      sacral plexus and paravertebral nerve block(LSP) group with 20ml 0.5% ropivacaine at lumbar
      plexus(level L3-4) , 10ml 0.5%ropivacaine at sacral plexus and 10ml 0.5%ropivacaine at
      paravertebral nerve(level L1). The target-controlled propofol infusion is started immediately
      after positioning the patient on the operating table. The initial target concentration was
      0.5μg/mL. The infusion rate is adjusted every 5min by increasing or decreasing the target
      concentration by 0.2μg/mL steps based on the patients' respiratory rate(RR), blood
      pressure(BP), heart rate(HR), and level of sedation(score of 5 on Ramsay Sedation Scale ).
      The minimal, maximal, optimal target concentration, cumulative propofol dose, frequency of
      spontaneous movement and incidences of associated complications are recorded. Patients were
      phoned for followup and questioned for activity status in one year. If the patients were
      dead, date of death; if they survived, daily living activity questioned.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cumulative propofol dose</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The optimal target concentration propofol</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Anesthesia; Reaction</condition>
  <arm_group>
    <arm_group_label>paravertebral nerve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) , 10ml 0.5%ropivacaine at sacral plexus and 10ml 0.5%ropivacaine at paravertebral nerve(level L1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lumbar and sacral plexus block</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>a lumbar and sacral plexus block(LS) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) and 10ml 0.5%ropivacaine at sacral plexus;</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>paravertebral nerve</intervention_name>
    <description>a lumbar, sacral plexus and paravertebral nerve block(LSP) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) , 10ml 0.5%ropivacaine at sacral plexus and 10ml 0.5%ropivacaine at paravertebral nerve(level L1).</description>
    <arm_group_label>paravertebral nerve</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lumbar and sacral plexus block</intervention_name>
    <description>a lumbar and sacral plexus block(LS) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) and 10ml 0.5%ropivacaine at sacral plexus;</description>
    <arm_group_label>lumbar and sacral plexus block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA Ⅰ-Ⅲ

          -  hip fracture need surgery

        Exclusion Criteria:

          -  patient refusal

          -  chronic use of opioids

          -  coagulation disorders

          -  preexisting neurological disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>80 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daqiang Zhao, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiaotong University Affiliated Sixth People's Hospital Shanghai,China</affiliation>
  </overall_official>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2014</study_first_submitted>
  <study_first_submitted_qc>April 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2014</study_first_posted>
  <last_update_submitted>December 30, 2014</last_update_submitted>
  <last_update_submitted_qc>December 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University Affiliated Sixth People’s Hospital</investigator_affiliation>
    <investigator_full_name>Daqiang Zhao</investigator_full_name>
    <investigator_title>Daqiang Zhao</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

